New evidence proves the safety of a robotic prostatectomy with the lowest complication rates in prostate cancer treatment.
According to a new study by The Cancer Institute of New Jersey (CINJ), it is no secret that robotic surgery results in shorter hospital stays, less blood loss and quicker recovery of sexual and urinary functions compared to […]

continue reading from " Robotic prostatectomy has low complication rates "

The researchers at the Fred Hutchinson Cancer Research Centre in Seattle, said that aspirin appears to dampen the effects of two particular enzymes that stimulate inflammation in the prostate. The biggest benefit appeared to be among those regularly taking a low daily dose of 75mg. Among this group, the chances of developing prostate cancer dropped […]

continue reading from " Men who had used aspirin less likely to develop a prostate tumour "

Today, the U.S. Food and Drug Administration approved Jevtana (cabazitaxel) to treat men with prostate cancer. Jevtana, a chemotherapy drug used in combination with the steroid prednisone, is the first treatment for advanced, hormone-refractory, prostate cancer that has worsened during or after treatment with docetaxel, a commonly used drug for advanced prostate cancer.Jevtana was reviewed under […]

continue reading from " FDA Approves New Treatment for Advanced Prostate Cancer "

Radiation experts from the University of Toronto’s Princess Margaret Hospital, Canada, are reporting a key advance in treating men with cancer that has started to spread beyond the prostate: survival is significantly better if radiation is added to standard hormone treatments.Copnclusions of the study were given Sunday at a cancer conference, where other research showed that an […]

continue reading from " Radiation boosts prostate cancer survival "

A recent study at Stanford University focused the impact of individual and combinations of common medications on serum total PSA in a large cross-sectional population study.
At the end of their work, the research team concluded that men who regularly consume NSAIDs, statins, and thiazide diuretics have reduced PSA levels by clinically relevant amounts. The concurrent […]

continue reading from " The impact of common medications on serum prostate-specific antigen levels "

The additional study results from the Phase III clinical trial evaluating toremifene 80 mg for the prevention of fractures in men with prostate cancer on androgen deprivation therapy will be presented by GTx, Inc.at the 2010 Annual Meeting of the American Urological Association being held in San Francisco May 29-June 3.
Multivariate analysis demonstrates treatment with […]

continue reading from " Toremifene reduces fracture risk after initiation of androgen deprivation therapy "

The U.S. Food and Drug Administration approved Provenge (sipuleucel-T), a drug indicated for the treatment of asymptomatic or minimally symptomatic prostate cancer that has spread to other parts of the body and is resistant to standard hormone treatment. Provenge opens a new therapy for certain men with advanced prostate cancer that uses their own immune […]

continue reading from " FDA approves a cellular immunotherapy for men with advanced prostate cancer "

The Wall Street Journal reports that two new studies suggest that the prolonged use of cancer medication helped stunt the progress of the disease, a shift from the scheduled courses of treatment typically delivered to patients.
According to the Journal, both studies show “how cancer is often becoming a chronic disease.” Regarding the drug Rituxan, one […]

continue reading from " Prolonged therapies can turn cancer into chronic disease "

A new study at the University of Alabama at Birmingham suggests the erectile dysfunction drug Viagra, and possibly other similar medications, may prompt long-term hearing loss among users,
In the May 18 issue of the Archives of Otolaryngology — Head and Neck Surgery, researchers discuss evidence supporting an association between the onset of hearing problems and […]

continue reading from " Viagra linked to hearing loss "

A U.S. Food and Drug Administration review has found a widely used class of prostate cancer drugs called gonadotropin-releasing hormone (GnRH) agonists increases the risk of diabetes, heart attack, stroke and sudden death in men.
Drugs in the GnRH agonist class include Eligard, Lupron, Synarel, Trelstar, Vantas, Viadur, Zoladex and several generic products. These drugs suppress […]

continue reading from " GnRH agonists increases the risk of diabetes, heart attack, stroke and sudden death in men "